128 related articles for article (PubMed ID: 21187512)
1. CA19.9 and CEA in transitional cell carcinoma of the bladder: serological and immunohistochemical findings.
Hegele A; Mecklenburg V; Varga Z; Olbert P; Hofmann R; Barth P
Anticancer Res; 2010 Dec; 30(12):5195-200. PubMed ID: 21187512
[TBL] [Abstract][Full Text] [Related]
2. [A case of transitional cell carcinoma of the urinary bladder with high serum level of CEA and CA19-9].
Inai H; Shimazui T; Yamamoto T; Yamauchi A; Uchida K; Takeshima H; Akaza H
Hinyokika Kiyo; 2001 Aug; 47(8):583-6. PubMed ID: 11579601
[TBL] [Abstract][Full Text] [Related]
3. [A case of CEA and CA19-9 producing recurrent transitional cell carcinoma in an Indiana pouch after total cystectomy].
Miyoshi Y; Asakura T; Matsuzaki J; Fukuda M; Satomi Y; Akabane H
Hinyokika Kiyo; 1996 Dec; 42(12):961-4. PubMed ID: 9013232
[TBL] [Abstract][Full Text] [Related]
4. [Usefulness of carcinoembryonic antigen in transitional cell carcinoma of the bladder].
Moreno Sierra J; Ortega MD; Blanco Jimenez E; Maestro de las Casas ML; Delgado Marti JA; Hermida Gutierrez J; Salinas Casado J; Esteban Fuertes M; Resel Estévez L
Arch Esp Urol; 1994; 47(1):39-42. PubMed ID: 8192496
[TBL] [Abstract][Full Text] [Related]
5. [A case of transitional cell carcinoma of renal pelvis with extremely high serum levels of CA19-9 and CEA].
Sugaya Y; Ochi M; Hashimoto S; Muraki J; Morita T; Kobayashi Y; Nakamura S; Tokue A
Hinyokika Kiyo; 1997 Jul; 43(7):495-9. PubMed ID: 9282296
[TBL] [Abstract][Full Text] [Related]
6. Comparison between tissue antigen analysis and plasma determinations for TPA and CEA in transitional cell carcinomas and in tumorfree urothelium of the urinary bladder.
Vogel J; Oehr P; Maisey R; Adolphs HD
Cancer Detect Prev; 1988; 11(3-6):389-96. PubMed ID: 2455597
[TBL] [Abstract][Full Text] [Related]
7. Expression of cytokeratin 20 in urinary cytology of patients with bladder carcinoma.
Klein A; Zemer R; Buchumensky V; Klaper R; Nissenkorn I
Cancer; 1998 Jan; 82(2):349-54. PubMed ID: 9445193
[TBL] [Abstract][Full Text] [Related]
8. Serum tumor markers may predict overall and disease specific survival in patients with clinically organ confined invasive bladder cancer.
Margel D; Tal R; Baniel J
J Urol; 2007 Dec; 178(6):2297-300; discussion 2300-1. PubMed ID: 17936837
[TBL] [Abstract][Full Text] [Related]
9. [A case of transitional cell carcinoma of the renal pelvis with adenocarcinoma producing CEA and CA19-9].
Matsuoka Y; Ishimaru H; Arai G; Aida J; Okada Y; Ito Y
Hinyokika Kiyo; 2004 Sep; 50(9):637-40. PubMed ID: 15518131
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical evaluation of nonspecific cross reactive antigen and carcinoembryonic antigen (CEA) in urinary bladder carcinoma.
Asamoto M; Fukushima S; Tatemoto Y; Yamada K; Yuba R; Mori M
Anticancer Res; 1989; 9(2):319-26. PubMed ID: 2751258
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of CA19-9 as a tumor marker in urothelial malignancy.
Chuang CK; Liao SK
Scand J Urol Nephrol; 2004; 38(5):359-65. PubMed ID: 15764245
[TBL] [Abstract][Full Text] [Related]
12. [Clinicopathological study of urinary bladder tumors. Clinical evaluation of immunohistochemistry in urine cytology].
Nagata Y; Kinoshita H; Kawamura N; Sasadaira S
Hinyokika Kiyo; 1985 Nov; 31(11):1931-7. PubMed ID: 4091136
[TBL] [Abstract][Full Text] [Related]
13. Blood group H antigen in transitional carcinoma of the urinary bladder.
Tichý M; Tichá V; Jansa P; Student V; Vanák J
Acta Univ Palacki Olomuc Fac Med; 1991; 130():157-62. PubMed ID: 1838863
[TBL] [Abstract][Full Text] [Related]
14. Accuracy of the ImmunoCyt assay in the diagnosis of transitional cell carcinoma of the urinary bladder.
Feil G; Zumbrägel A; Päulgen-Nelde HJ; Hennenlotter J; Maurer S; Krause S; Bichler KH; Stenzl A
Anticancer Res; 2003; 23(2A):963-7. PubMed ID: 12820331
[TBL] [Abstract][Full Text] [Related]
15. Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.
Guadagni F; Kantor J; Aloe S; Carone MD; Spila A; D'Alessandro R; Abbolito MR; Cosimelli M; Graziano F; Carboni F; Carlini S; Perri P; Sciarretta F; Greiner JW; Kashmiri SV; Steinberg SM; Roselli M; Schlom J
Cancer Res; 2001 Mar; 61(6):2523-32. PubMed ID: 11289125
[TBL] [Abstract][Full Text] [Related]
16. A comparison of tumour M2-PK with carcinoembryonic antigen and CA19-9 in patients undergoing liver resection for colorectal metastases.
Kumar Y; Pinedo IR; Tapuria N; Zabron A; Davidson BR
Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1006-11. PubMed ID: 18787469
[TBL] [Abstract][Full Text] [Related]
17. Relationship of blood groups and transitional cell carcinoma of the bladder.
Kirkali Z; Eryigit M
Int Urol Nephrol; 1993; 25(3):255-7. PubMed ID: 8225826
[TBL] [Abstract][Full Text] [Related]
18. ABO blood groups and their relationship to transitional cell carcinoma of the urinary bladder in 30 Jordanian patients.
Murshidi MS
Acta Urol Belg; 1988; 56(4):517-22. PubMed ID: 3207084
[No Abstract] [Full Text] [Related]
19. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B
Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921
[TBL] [Abstract][Full Text] [Related]
20. The value of CEA assay in tissue, serum and urine in patients with transitional cell carcinoma of the bladder.
Alampi G; Ronchi E; Galassi A; Soli M; Botteghi B; Bercovich E
Arch Anat Cytol Pathol; 1985; 33(4):193-6. PubMed ID: 3904640
[No Abstract] [Full Text] [Related]
[Next] [New Search]
